D-1533-2020 Class II Terminated

Recalled by Hikma Pharmaceuticals USA Inc. — Cherry Hill, NJ

Recall Details

Product Type
Drugs
Report Date
September 2, 2020
Initiation Date
August 14, 2020
Termination Date
June 10, 2021
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
97,890 vials

Product Description

Buprenorphine HCl Injection, 0.3 mg/mL, 1 mL vial, For Intramuscular or Intravenous Use Only, Rx Only, Manufactured by: Hikma Farmaceutica, Portugal S.A., Distributed by: Hikma Pharmaceuticals, Eatontown, NJ 07724, USA Inc., NDC: 0143-9246-01.

Reason for Recall

Sub-potent Drug: Out-of-Specification assay results found at 3 month stability testing.

Distribution Pattern

Nationwide in the U.S.

Code Information

Lot #s: 2005023.1, 2005024.1, 2005025.1, Exp 02/28/2021